Physician profile
David W Morledge
NPI 1225129703
$127,725.29
in general payments reported to CMS, 2019-2025
80 companies · $43.67 in 2025
The $43.67 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $18K · 2021: $24K · 2022: $26K · 2023: $19K · 2024: $20K · 2025: $43.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $7,123 · Travel and Lodging: $3,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,818.75 |
| Food and Beverage | $7,122.64 |
| Travel and Lodging | $3,053.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70,740.72 | 2019-2025 | |
| Allergan, INC. | $28,874.75 | 2019-2022 | |
| Mdd US Operations, LLC | $10,442.05 | 2019-2024 | Gocovri, Gocovri, Apokyn |
| Genentech, INC. | $2,020.00 | 2022 | |
| Genentech USA, INC. | $1,173.19 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $1,085.51 | 2019-2025 | |
| Biogen, INC. | $852.59 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $814.37 | 2019-2024 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $793.70 | 2019-2024 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $668.23 | 2019-2024 | Nuplazid |
| Amgen INC. | $609.81 | 2019-2023 | Aimovig |
| Acorda Therapeutics, INC | $527.34 | 2019-2024 | Inbrija, Ampyra |
| Genzyme Corporation | $522.79 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $453.25 | 2019-2022 | |
| Lilly USA, LLC | $434.80 | 2019-2024 | Amyvid, Reyvow, Emgality |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.